ArticleScientific reports2026
Multimodal evaluation of mannose engineered poly lactic glycolic acid nanoparticles with granulocyte colony stimulating factor focused delivery to bone marrow for neutropenia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neutropenia, characterized by a critical reduction in neutrophils, demands targeted therapeutic strategies to enhance the delivery efficiency of granulocyte colony-stimulating factor (G-CSF) specifically to bone marrow macrophages. This study focused on engineering mannose-modified poly(D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) to achieve ligand-directed delivery of G-CSF. Mannose anchoring was achieved via Ethylenediamine (EDA)-mediated chemical ligation using N-hydroxysulfosuccinimide (NHS) and dicyclocarbodiimide as coupling agents, resulting in Mn-EDA-PLGA NPs. G-CSF-loaded and placebo NPs were fabricated through a multiple emulsion solvent evaporation method and subjected to comprehensive physicochemical characterization. The developed placebo Mn-EDA-PLGA NPs measured 199 ± 12 nm, while G-CSF-loaded Mn-EDA-PLGA NPs measured 153 ± 12.2 nm, both exhibiting a negative surface charge of − 40.07 ± 1.1 mV and − 34.9 ± 1.9 mV, respectively. Polydispersity index values were low (0.34 and 0.41), indicating uniform particle distribution. Entrapment efficiencies were significant, with the optimized G-CSF-loaded formulation achieving 72.6% drug encapsulation efficiency and drug loadings of 5 µg and 3 µg for placebo and active NPs, respectively. Scanning electron microscopy confirmed spherical morphology with smooth surfaces. Biological evaluation using scintigraphy and flow cytometry in J774.2 macrophage cells validated the targeting efficiency of mannose-modified NPs. Furthermore, molecular docking and molecular dynamics simulations substantiated the stability and interaction profile of G-CSF within the nanocarrier system. The convergence of in vitro, in vivo, and silico findings underscores the potential of Mn-EDA-PLGA NPs as a robust delivery vehicle for G-CSF, offering enhanced bone marrow macrophage targeting. This targeted approach holds promise for improving therapeutic outcomes in neutropenia by maximising drug localization and minimising systemic exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.